Sophic files Form 144 to sell 760 RSUs

Sophic Biosciences reports a proposed sale of restricted stock units by an affiliate.

Rhea-AI Filing Summary

Sophic Biosciences reports a proposed sale of restricted stock units by an affiliate. The filing lists 760 restricted stock units proposed for sale on 02/18/2026. The notice also records prior 10b5-1 sales by the same affiliate, including 4,200 shares on 01/06/2026 and 2,021 shares on 01/05/2026.

Insights

Insider Transactions Analyst

Routine Form 144 sale notice: small insider sale of RSUs and recent 10b5-1 trades.

The filing records a proposed sale of 760 restricted stock units on 02/18/2026, consistent with an affiliate-managed disposition. It separately lists multiple executed 10b5-1 sales in December 2025 and January 2026.

These items are administrative disclosures of planned and completed sales; cash‑flow treatment and proceeds recipients are not detailed in the excerpt. Subsequent filings or transaction confirmations would provide trade execution and settlement details.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the SOPH Form 144 disclose?

The filing discloses a proposed sale of 760 restricted stock units on 02/18/2026. It also lists several completed 10b5-1 sales, with sample trades of 4,200 and 2,021 shares in January 2026.

Who is the seller in the SOPH Form 144?

The excerpt identifies an affiliate associated with the filing as the seller, listed by name for past 10b5-1 trades. The document shows multiple trades attributed to Ross J Muken across December 2025 and January 2026.

How many shares were sold recently under 10b5-1 plans?

The filing lists multiple recent 10b5-1 sales including sample transactions of 4,200 shares on 01/06/2026 and 2,021 shares on 01/05/2026. Several other smaller sales are also recorded in the excerpt.

Does the Form 144 state who receives the proceeds?

The provided excerpt does not state which party receives cash proceeds. It lists quantities and dates of proposed and completed sales but does not describe proceeds allocation or use.

Are the proposed RSUs being sold subject to conditions?

The filing shows the proposed sale date as 02/18/2026 for 760 restricted stock units. The excerpt does not attach qualifiers like "subject to approval" or similar conditions to that line.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/19/2026 - 04:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002005463
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SOPHIA GENETICS SA
SEC File Number	001-40627
Address of Issuer	La Piece 12 ch-1180 Rolle SWITZERLAND 00000
Phone	41216941060
Name of Person for Whose Account the Securities are To Be Sold	ROSS J MUKEN
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	760	3670.80	67847058	02/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/18/2026	Restricted Stock Units	Issuer			760	02/18/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	01/20/2026	760	4077.78
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	01/06/2026	4200	20013.84
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	01/05/2026	2021	9319.64
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	12/26/2025	1689	7880.71
10b5-1 Sales for ROSS J MUKEN La Piece 12 ch-1180 Rolle V8 00000	Common	12/19/2025	761	3523.13

144: Remarks and Signature

Remarks
Date of Notice	02/19/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Ross J Muken
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)